Rona M Smith, Rachel B Jones, Ulrich Specks, Simon Bond, Marianna Nodale, Reem Al-Jayyousi, Jacqueline Andrews, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Vimal Derebail, Tim Doulton, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz-Singer, Lorraine Harper, Toshiko Ito-Ihara, Nader Khalidi, Rainer Klocke, Curry Koening, Yoshinori Komagata, Carol Langford, Peter Lanyon, Raashid Luqmani, Carol McAlear, Larry W Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Rennie L Rhee, Robert Spiera, Antoine G Sreih, Vladamir Tesar, Giles Walters, Caroline Wroe, David Jayne, Peter A Merkel
OBJECTIVE: Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of relapse. Relapses are associated with increased exposure to immunosuppressive medications, the accrual of damage and increased morbidity and mortality. The RITAZAREM trial compared the efficacy of repeat-dose rituximab to daily oral azathioprine for prevention of relapse in patients with relapsing AAV in whom remission was reinduced with rituximab...
March 23, 2023: Annals of the Rheumatic Diseases
Dandan Chen, Hanlin Yin, Le Zhang, Fubin Li, Liangjing Lu
No abstract text is available yet for this article.
March 21, 2023: Annals of the Rheumatic Diseases
Nerea Alonso, Omar M E Albagha, Asim Azfer, Beatriz Larraz-Prieto, Kathryn Berg, Philip L Riches, Barbara Ostanek, Tomaz Kocjan, Janja Marc, Bente L Langdahl, Stuart H Ralston
OBJECTIVES: Teriparatide (TPTD) is an effective treatment for osteoporosis but the individual response to therapy is variable for reasons that are unclear. This study aimed to determine whether the response to TPTD might be influenced by genetic factors. METHODS: We searched for predictors of the response of bone mineral density (BMD) to TPTD using a two-stage genome-wide association study in 437 patients with osteoporosis from three referral centres. Demographic and clinical data including the response of BMD to treatment at the lumbar spine and hip were extracted from the medical records of each participant...
March 20, 2023: Annals of the Rheumatic Diseases
Lars Erik Kristensen, Silvio Danese, Arne Yndestad, Cunshan Wang, Edward Nagy, Irene Modesto, Jose Rivas, Birgitta Benda
OBJECTIVES: Based on primary results from ORAL Surveillance, an event-driven clinical trial of risk-enriched patients, identify subpopulations with different relative risk (ie, 'high-risk' and 'low-risk') with tofacitinib versus tumour necrosis factor inhibitors (TNFi). METHODS: Patients with rheumatoid arthritis aged ≥50 years with ≥1 additional cardiovascular risk factor received tofacitinib 5 or 10 mg two times a day or TNFi. Prior analyses had identified age and smoking as risk factors of particular interest across safety outcomes...
March 17, 2023: Annals of the Rheumatic Diseases
Unnur Styrkarsdottir, Lilja Stefansdottir, Gudmar Thorleifsson, Olafur A Stefansson, Saedis Saevarsdottir, Sigrun H Lund, Thorunn Rafnar, Kazuyuki Hoshijima, Kendra Novak, Natividad Oreiro, Ignacio Rego-Perez, Channing Hansen, Nikolas Kazmers, Lambertus A Kiemeney, Francisco J Blanco, Tyler Barker, Margreet Kloppenburg, Michael J Jurynec, Daniel F Gudbjartsson, Helgi Jonsson, Unnur Thorsteinsdottir, Kari Stefansson
OBJECTIVES: Erosive hand osteoarthritis (EHOA) is a severe subset of hand osteoarthritis (OA). It is unclear if EHOA is genetically different from other forms of OA. Sequence variants at ten loci have been associated with hand OA but none with EHOA. METHODS: We performed meta-analysis of EHOA in 1484 cases and 550 680 controls, from 5 populations. To identify causal genes, we performed eQTL and plasma pQTL analyses, and developed one zebrafish mutant. We analysed associations of variants with other traits and estimated shared genetics between EHOA and other traits...
March 17, 2023: Annals of the Rheumatic Diseases
Reem Assi, Chahrazad Cherifi, Frederique M F Cornelis, Qiongfei Zhou, Lies Storms, Sofia Pazmino, Rodrigo Coutinho de Almeida, Ingrid Meulenbelt, Rik J Lories, Silvia Monteagudo
OBJECTIVES: In osteoarthritis, methylation of lysine 79 on histone H3 (H3K79me), a protective epigenetic mechanism, is reduced. Histone methylation levels are dynamically regulated by histone methyltransferases and demethylases. Here, we aimed to identify which histone demethylases regulate H3K79me in cartilage and investigate whether their targeting protects against osteoarthritis. METHODS: We determined histone demethylase expression in human non-osteoarthritis and osteoarthritis cartilage using qPCR...
March 16, 2023: Annals of the Rheumatic Diseases
Bernhard Hellmich, Beatriz Sanchez-Alamo, Jan H Schirmer, Alvise Berti, Daniel Blockmans, Maria C Cid, Julia U Holle, Nicole Hollinger, Omer Karadag, Andreas Kronbichler, Mark A Little, Raashid A Luqmani, Alfred Mahr, Peter A Merkel, Aladdin J Mohammad, Sara Monti, Chetan B Mukhtyar, Jacek Musial, Fiona Price-Kuehne, Mårten Segelmark, Y K Onno Teng, Benjamin Terrier, Gunnar Tomasson, Augusto Vaglio, Dimitrios Vassilopoulos, Peter Verhoeven, David Jayne
BACKGROUND: Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials have been published that have the potential to change clinical care and support the need for an update. METHODS: Using EULAR standardised operating procedures, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 16 countries...
March 16, 2023: Annals of the Rheumatic Diseases
Saeko Yamada, Yasuo Nagafuchi, Min Wang, Mineto Ota, Hiroaki Hatano, Yusuke Takeshima, Mai Okubo, Satomi Kobayashi, Yusuke Sugimori, Nakano Masahiro, Ryochi Yoshida, Norio Hanata, Yuichi Suwa, Yumi Tsuchida, Yukiko Iwasaki, Shuji Sumitomo, Kanae Kubo, Kenichi Shimane, Keigo Setoguchi, Takanori Azuma, Hiroko Kanda, Hirofumi Shoda, Xuan Zhang, Kazuhiko Yamamoto, Kazuyoshi Ishigaki, Tomohisa Okamura, Keishi Fujio
OBJECTIVES: Little is known about the immunology underlying variable treatment response in rheumatoid arthritis (RA). We performed large-scale transcriptome analyses of peripheral blood immune cell subsets to identify immune cells that predict treatment resistance. METHODS: We isolated 18 peripheral blood immune cell subsets of 55 patients with RA requiring addition of new treatment and 39 healthy controls, and performed RNA sequencing. Transcriptome changes in RA and treatment effects were systematically characterised...
March 14, 2023: Annals of the Rheumatic Diseases
Shiri Keret, Tsila Zuckerman, Israel Henig, Tova Rainis, Safwat Odeh, Naim Artoul, Aniela Shouval, Gleb Slobodin, Doron Rimar
No abstract text is available yet for this article.
March 13, 2023: Annals of the Rheumatic Diseases
Dionysis Nikolopoulos, Theodora Manolakou, Alexia Polissidis, Anastasia Filia, George Bertsias, Yassemi Koutmani, Dimitrios T Boumpas
INTRODUCTION: Inflammatory mediators are detected in the cerebrospinal fluid of systemic lupus erythematosus patients with central nervous system involvement (NPSLE), yet the underlying cellular and molecular mechanisms leading to neuropsychiatric disease remain elusive. METHODS: We performed a comprehensive phenotyping of NZB/W-F1 lupus-prone mice including tests for depression, anxiety and cognition. Immunofluorescence, flow cytometry, RNA-sequencing, qPCR, cytokine quantification and blood-brain barrier (BBB) permeability assays were applied in hippocampal tissue obtained in both prenephritic (3-month-old) and nephritic (6-month-old) lupus mice and matched control strains...
March 10, 2023: Annals of the Rheumatic Diseases
Joerg Christoph Henes, Ioana Martac, Wichard Vogel, Claudia Lengerke, Reinhild Klein, Luca Hensen, Ann-Christin Pecher
No abstract text is available yet for this article.
March 8, 2023: Annals of the Rheumatic Diseases
Sofia Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert Bm Landewé, Désirée van der Heijde
No abstract text is available yet for this article.
March 6, 2023: Annals of the Rheumatic Diseases
Viking Huss, Hannah Bower, Karin Hellgren, Thomas Frisell, Johan Askling
OBJECTIVE: Assess cancer risks with Janus kinase inhibitors (JAKi) versus biological disease-modifying antirheumatic drugs (bDMARDs) in clinical practice. METHODS: Cohort study of patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) initiating treatment with JAKi, tumour necrosis factor inhibitors (TNFi) or other (non-TNFi) bDMARDs 2016-2020 using prospectively collected data from the Swedish Rheumatology Quality Register linked to other registers including the Cancer Register...
March 3, 2023: Annals of the Rheumatic Diseases
Taotao Li, Changrong Ge, Alexander Krämer, Outi Sareila, Monica Leu Agelii, Linda Johansson, Kristina Forslind, Erik Lönnblom, Min Yang, Bingze Xu, Qixing Li, Lei Cheng, Göran Bergström, Gonzalo Fernandez, Alf Kastbom, Solbritt Rantapää-Dahlqvist, Inger Gjertsson, Rikard Holmdahl
OBJECTIVES: To identify the arthritogenic B cell epitopes of glucose-6-phosphate isomerase (GPI) and their association with rheumatoid arthritis (RA). METHODS: IgG response towards a library of GPI peptides in patients with early RA, pre-symptomatic individuals and population controls, as well as in mice, were tested by bead-based multiplex immunoassays and ELISA. Monoclonal IgG were generated, and the binding specificity and affinity were determined by ELISA, gel size exclusion chromatography, surface plasma resonance and X-ray crystallography...
March 1, 2023: Annals of the Rheumatic Diseases
Javier Rodríguez-Carrio, Agata Burska, Philip G Conaghan, Willem A Dik, Robert Biesen, Maija-Leena Eloranta, Giulio Cavalli, Marianne Visser, Dimitrios T Boumpas, George Bertsias, Marie Wahren-Herlenius, Jan Rehwinkel, Marie-Louise Frémond, Mary K Crow, Lars Rönnblom, Marjan A Versnel, Edward M Vital
BACKGROUND: Type I interferons (IFN-Is) play a role in a broad range of rheumatic and musculoskeletal diseases (RMDs), and compelling evidence suggests that their measurement could have clinical value, although testing has not progressed into clinical settings. OBJECTIVE: To develop evidence-based points to consider (PtC) for the measurement and reporting of IFN-I assays in clinical research and to determine their potential clinical utility. METHODS: EULAR standardised operating procedures were followed...
March 1, 2023: Annals of the Rheumatic Diseases
Christian Dejaco, Andreas Kerschbaumer, Daniel Aletaha, Milena Bond, Elvis Hysa, Dario Camellino, Lisa Ehlers, Andy Abril, Simone Appenzeller, Maria C Cid, Bhaskar Dasgupta, Christina Duftner, Peter C Grayson, Bernhard Hellmich, Alojzija Hočevar, Tanaz A Kermani, Eric L Matteson, Susan P Mollan, Lorna Neill, Cristina Ponte, Carlo Salvarani, Sebastian Eduardo Sattui, Wolfgang A Schmidt, Philip Seo, Josef S Smolen, Jens Thiel, Carlos Enrique Toro-Gutiérrez, Madeline Whitlock, Frank Buttgereit
OBJECTIVES: To develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). METHODS: A systematic literature review was conducted to retrieve data on treatment targets and outcomes in GCA/PMR as well as to identify the evidence for the effectiveness of a T2T-based management approach in these diseases. Based on evidence and expert opinion, the task force (29 participants from 10 countries consisting of physicians, a healthcare professional and a patient) developed recommendations, with consensus obtained through voting...
February 24, 2023: Annals of the Rheumatic Diseases
Bente Glintborg, Daniela Di Giuseppe, Johan Karlsson Wallman, Dan C Nordström, Bjorn Gudbjornsson, Merete Lund Hetland, Johan Askling, Gerdur Grondal, Tuulikki Sokka, Sella A Provan, Brigitte Michelsen, Eirik Klami Kristianslund, Lene Dreyer, Thorvardur Jon Love, Ulf Lindström
BACKGROUND: We aimed to describe the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) in the Nordic countries and to compare their retention and effectiveness. METHODS: Patients with PsA starting a b/tsDMARD in 2012-2020 in five Nordic rheumatology registers were included. Uptake and patient characteristics were described, with comorbidities identified from linkages to national patient registries...
February 22, 2023: Annals of the Rheumatic Diseases
Samantha Louise Smith, Sheree Alexander, Nisha Nair, Sebastien Viatte, Stephen Eyre, Kimme L Hyrich, Ann W Morgan, Anthony G Wilson, John D Isaacs, Darren Plant, Anne Barton
OBJECTIVES: The inflammatory protein calprotectin (MRP8/14) has been identified as a promising biomarker of treatment response in rheumatoid arthritis (RA). Our aim was to test MRP8/14 as a biomarker of response to tumour necrosis factor (TNF)-inhibitors in the largest RA cohort to date and to compare with C-reactive protein (CRP). METHODS: Serum MRP8/14 was measured in 470 patients with RA about to commence treatment with adalimumab (n=196) or etanercept (n=274)...
February 21, 2023: Annals of the Rheumatic Diseases
Scott R Henderson, Harry Horsley, Paul Frankel, Maryam Khosravi, Talya Goble, Stephen Carter, Marilina Antonelou, Rhys D R Evans, Xiang Zhang, Tai-Ying Chu, Hsi-Hsien Lin, Siamon Gordon, Alan David Salama
OBJECTIVES: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are autoimmune vasculitides associated with antineutrophil cytoplasm antibodies that target proteinase 3 (PR3) or myeloperoxidase (MPO) found within neutrophils and monocytes. Granulomas are exclusively found in GPA and form around multinucleated giant cells (MGCs), at sites of microabscesses, containing apoptotic and necrotic neutrophils. Since patients with GPA have augmented neutrophil PR3 expression, and PR3-expressing apoptotic cells frustrate macrophage phagocytosis and cellular clearance, we investigated the role of PR3 in stimulating giant cell and granuloma formation...
February 17, 2023: Annals of the Rheumatic Diseases
Christian Dejaco, Sofia Ramiro, Zahi Touma, Milena Bond, Medha Soowamber, Catalina Sanchez-Alvarez, Carol A Langford
Glucocorticoids (GCs) are the gold standard for treatment of giant cell arteritis (GCA); however, there is a need for studies on GC-sparing agents, given that up to 85% of patients receiving GC only develop adverse events. Previous randomised controlled trials (RCTs) have applied different primary endpoints, limiting the comparison of treatment effects in meta-analyses and creating an undesired heterogeneity of outcomes. The harmonisation of response assessment is therefore an important unmet need in GCA research...
February 17, 2023: Annals of the Rheumatic Diseases
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.